The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Historic OS Benefit Seen in Phase II Glioblastoma Study

David Reardon, MD
Published Online: 10:41 PM, Wed June 24, 2015
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, and president, Society for Neuro-Oncology, discusses rindopepimut (CDX-110), a synthetic peptide vaccine, and its potential in glioblastoma multiforme, based an extension in progression-free survival and overall survival seen in the phase II ReACT Trial.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.